60 Degrees Pharmaceuticals (NASDAQ: SXTP) CEO Geoff Dow will participate in the Healing Lyme Summit from April 15-21, 2025, to discuss babesiosis, a tick-borne disease commonly occurring alongside Lyme disease. Dr. Dow will address the increasing prevalence of babesiosis in the United States, clinical challenges, and the need for better diagnostic and treatment options.
The company is currently conducting two clinical trials (NCT06207370 and NCT06478641) evaluating tafenoquine for treating severe babesiosis and persistent disease in immunosuppressed patients. The summit is a free virtual event featuring scientific discussions and educational content on tick-borne illnesses.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.